Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly

[1]  S. Yin,et al.  Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience , 2018, Clinical Neurology and Neurosurgery.

[2]  L. Tshibanda,et al.  T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. , 2016, Endocrine-related cancer.

[3]  T. Brue,et al.  The risks of overlooking the diagnosis of secreting pituitary adenomas , 2016, Orphanet Journal of Rare Diseases.

[4]  S. Pita-Fernández,et al.  Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. , 2015, European journal of internal medicine.

[5]  A. Hoffman,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY? , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[6]  C. Luo,et al.  Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis , 2015, Brain and Development.

[7]  J. Bevan,et al.  Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long? , 2014, Clinical endocrinology.

[8]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[9]  J. Svartberg,et al.  Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. , 2014, European journal of endocrinology.

[10]  S. Melmed,et al.  Immune modulation in humans: implications for type 1 diabetes mellitus , 2014, Nature Reviews Endocrinology.

[11]  A. Tabarin,et al.  Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial , 2013, The Journal of clinical endocrinology and metabolism.

[12]  S. Pita-Fernández,et al.  Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis , 2013, PloS one.

[13]  J. Gaudart,et al.  Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients , 2013, Clinical endocrinology.

[14]  J. Ramm-Pettersen,et al.  Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly , 2012, Clinical endocrinology.

[15]  Julian R. E. Davis,et al.  Acromegaly Surgery in Manchester Revisited: The Impact of Reducing Surgeon Numbers and the 2010 Consensus Guidelines for Disease Remission , 2012 .

[16]  Z. Quan,et al.  Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma , 2012, The Journal of international medical research.

[17]  Julian R. E. Davis,et al.  Acromegaly surgery in Manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission , 2012, Clinical endocrinology.

[18]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[19]  Z. Mao,et al.  Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. , 2010, European journal of endocrinology.

[20]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[21]  J. Hald,et al.  Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  F. Esposito,et al.  Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. , 2008, The Journal of clinical endocrinology and metabolism.

[23]  G. Lombardi,et al.  Acromegaly and the Cardiovascular System , 2006, Neuroendocrinology.

[24]  K. Abbassioun,et al.  A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years. , 2006, Surgical neurology.

[25]  J. Barth,et al.  Consensus statement on the standardisation of GH assays. , 2006, European journal of endocrinology.

[26]  M. Losa,et al.  Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. , 2006, Journal of neurosurgery.

[27]  C. Ersoy,et al.  Outcome of Surgery for Acromegaly Performed by Different Surgeons: Importance of Surgical Experience , 2005, Pituitary.

[28]  U. Plöckinger,et al.  Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study , 2005, Acta Neurochirurgica.

[29]  M. Zwahlen,et al.  Treatment outcomes and mortality of 94 patients with acromegaly , 2005, Acta Neurochirurgica.

[30]  M. Catalá,et al.  Preoperative lanreotide treatment for GH‐secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage , 2003, Clinical endocrinology.

[31]  S. Melmed,et al.  Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. , 2003, The Journal of clinical endocrinology and metabolism.

[32]  P. Chanson,et al.  Guidelines for acromegaly management. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  D. Lüdecke,et al.  Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. , 2001, European journal of endocrinology.

[34]  P. Stewart,et al.  Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. , 1999, QJM : monthly journal of the Association of Physicians.

[35]  Stratton,et al.  Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience , 1999, Clinical endocrinology.

[36]  Davis,et al.  The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma , 1998, Clinical endocrinology.

[37]  P. Cappabianca,et al.  Effect of octreotide pretreatment on surgical outcome in acromegaly. , 1997, The Journal of clinical endocrinology and metabolism.

[38]  P. Wrightson,et al.  Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.

[39]  A. Beckers,et al.  Presurgical Octreotide: treatment in acromegaly. , 1993, Metabolism: Clinical and Experimental.

[40]  Y. Mao,et al.  Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. , 2010, Endocrine journal.

[41]  J. Schramm,et al.  Does Octreotide Treatment Improve the Surgical Results of Macro-Adenomas in Acromegaly? A Randomized Study , 1999, Acta Neurochirurgica.

[42]  J. Honegger,et al.  Evidence supporting surgery as treatment of choice for acromegaly. , 1997, The Journal of endocrinology.

[43]  P. Del Monte,et al.  The impact of obesity on hormonal parameters in hirsute and nonhirsute women. , 1996, Metabolism: clinical and experimental.

[44]  A. Harris,et al.  Presurgical octreotide treatment in acromegaly. , 1992, Metabolism: clinical and experimental.